What sector is ESLA in?

Estrella Immunopharma, Inc. Common Stock (ESLA) operates in the Healthcare sector, specifically in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

What is ESLA's market cap?

Estrella Immunopharma, Inc. Common Stock (ESLA) has a market capitalization of $65M.

How can I analyze ESLA stock?

Valhalla provides comprehensive analysis for ESLA including institutional trade flow, dark pool activity, options data, technical indicators, and proprietary scoring. Visit valhalla-labs.io/stocks/ESLA for a full breakdown.

Where can I find institutional trades for ESLA?

Valhalla tracks real-time institutional trade flow for ESLA, including dark pool blocks, lit block trades, and sweep orders. These insights help identify where smart money is positioned.

ESLA

Q: What is ESLA (Estrella Immunopharma, Inc. Common Stock)?

Estrella Immunopharma, Inc. Common Stock (ESLA) is a healthcare company in the biological products, (no diagnostic substances) industry. Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates inc

Estrella Immunopharma, Inc. Common Stock

Healthcare — BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Valhalla Score 58

$1.63

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Latest Healthcare Sector News

ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGCNew York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Regencell Bioscie...newsfilecorp.com — May 1, 2026

📊 Key Statistics

Market Cap$65M

P/E Ratio—

EPS (TTM)—

EPS YoY—

Revenue YoY—

Float—

Short Float %—

Inst. Ownership—

Sector RS—

📈 Fundamentals

ROE—

ROIC—

ROA—

Current Ratio—

Debt/Equity—

Gross Margin—

Net Margin—

Dividend Yield—

Next Earnings—

⚡ Options Summary

Call OI—

Put OI—

P/C Ratio (OI)—

Gamma Environment—

Max Pain—

Call Wall—

Put Wall—

🎯 Analyst Estimates

Consensus Target—

High Target—

Low Target—

Analysts—

Upside/Downside—

📋 Quarterly Financials

Period	Revenue	Rev YoY	EPS	EPS YoY	Gross Margin

Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

Type	Strike	Exp	Size	Premium	Time

Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

Type	Price	Size	Value	Venue	Time

Start Free Trial Full insider & congressional trade history

👤 Insider Trades

Name	Type	Shares	Price	Date

Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

Institution	Shares	Value	% of Class